BioPorto Nears US Approval After Positive Kidney Test Data

Positive Clinical Results: BioPorto reported a <strong class="body_output text-content_primary font-semibold" node="[object Object]">successful preliminary analysis from its U.S. adult NGAL Cutoff Study, validating the test&#x27;s performance in assessing AKI risk.
Regulatory Milestone: The company plans a <strong class="body_output text-content_primary font-semibold" node="[object Object]">pre-submission to U.S. regulators by the end of Q1 2026, marking a critical step toward market approval.
Market Impact: The news significantly de-risks the asset and is expected to act as a <strong class="body_output text-content_primary font-semibold" node="[object Object]">major catalyst for BioPorto&#x27;s stock (CPH: BIOPOR) by unlocking a substantial U.S. revenue stream.

Positive Trial Data Bolsters Kidney Test on March 18

BioPorto A/S (CPH: BIOPOR) announced on March 18, 2026, that it has successfully completed the preliminary analysis of its U.S. adult NGAL Cutoff Study. The positive clinical readout marks a significant step forward for the company's diagnostic test designed to assess the risk of acute kidney injury (AKI). The study was structured to evaluate the clinical performance of the NGAL test, a key product in BioPorto's pipeline aimed at improving patient outcomes through early risk detection.

Pre-Submission Targets End of Q1 2026, Unlocking US Market

Following the encouraging clinical data, BioPorto confirmed it expects to complete a pre-submission to U.S. regulators by the end of the first quarter of 2026. This milestone is a major de-risking event for the company and its investors, creating a clear pathway toward commercialization. Gaining access to the United States is critical for BioPorto's growth strategy, as it would unlock a substantial revenue stream from the large diagnostics market for acute kidney injury. The positive results are expected to serve as a strong catalyst for the company's stock as it progresses toward U.S. approval.